Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190377 | 1.00 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL8776005 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL933037 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL190003 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL6374582 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL15798473 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL6374591 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL65892 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL12903446 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL190328 | 0.76 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-2488182-A1 | TREATING NEUROTOXICITY ASSOCIATED WITH COMBINATIONS OF 5 - FU OR ITS PRODRUGS AND DPD INHIBITORS | Adherex Technologies, Inc. (CA) | 2012-08-22 | — | — | EP | claimed |
| WO-2011047195-A1 | TREATING NEUROTOXICITY ASSOCIATED WITH COMBINATIONS OF 5 - FU OR ITS PRODRUGS AND DPD INHIBITORS | ADHEREX TECHNOLOGIES, INC. (CA) | 2011-04-21 | — | — | WO | claimed |
| WO-2009100367-A2 | COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME | ADHEREX TECHNOLOGIES INC. (CA) | 2009-08-13 | — | — | WO | claimed |
| EP-1827443-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | Adherex Technologies, Inc. (CA) | 2007-09-05 | — | — | EP | claimed |
| WO-2006060697-A9 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES INC (CA) | 2006-09-21 | — | — | WO | claimed |
| WO-2006060697-A1 | METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS | ADHEREX TECHNOLOGIES, INC. (CA) | 2006-06-08 | — | — | WO | claimed |
| EP-0726904-A1 | 5-FLUOROURACIL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| WO-1995012606-A1 | 5-FLUOROURACIL DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-11 | — | — | WO | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-0649840-A1 | Bis(hydroxymethyl)cyclopropylmethyl pyrimidine derivatives, their preparation and their use as anti-viral agents | Ajinomoto Co., Inc. (JP) | 1995-04-26 | — | — | EP | disclosed |
| EP-0539442-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001452-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | disclosed |
| US-4668778-A | Nucleoside 5'-alkyl- or alkenylphosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0097376-B1 | NUCLEOSIDE 5'-ALKYL- OR ALKENYLPHOSPHATE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1986-09-17 | — | — | EP | disclosed |
| EP-0097376-A1 | Nucleoside 5'-alkyl- or alkenylphosphate | Yamasa Shoyu Kabushiki Kaisha (JP) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | DPYD 35/4885MAPT 4192/4885ALDH1A1 2152/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | DPYD 36/4885MAPT 4237/4885ALDH1A1 1877/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.